Moderna

Moderna’s $200 Million R&D Trim Turns a Beat Into a Test of Discipline

Moderna’s Profit Turnaround Meets a Patent Truce and a Melanoma Bet

Brett Shapiro -

Moderna’s Stock Is Trading Two Stories at Once, and Only One Reports on November 6

Brett Shapiro -

Moderna’s 646% Run Meets a Wall Street Reckoning as Melanoma Data Head to the NEJM

Moderna’s Split Verdict: A Raised Target, a Downgrade, and a Stock Sale Nobody Should Misread

kashif hafeez -

Moderna’s Pipeline Widens Beyond Melanoma, but Each Study Stands on Its Own

kashif hafeez -

Moderna’s Melanoma Win Is Clinically Real. Citi’s Sell Call Says the Economics Aren’t.

kashif hafeez -

Moderna’s Melanoma Win Is Real. The Economics of Making It Are the Open Question.

kashif hafeez -

Moderna’s October Script Has Two Storylines, and Only One of Them Is Clinical

Moderna’s Calendar Is Crowded, but Only Two Entries Carry Real Weight

kashif hafeez -

Moderna’s Friday Slide Says More About Positioning Than About Science

Brett Shapiro -

Moderna’s Split Screen: Index Demand and Analyst Doubts Collide Ahead of Two Autumn Catalysts

Moderna’s Next Real Test: Two Dates in Late 2026, Not the Index Seat It Already Has

Brett Shapiro -

Citi’s Sell Call Exposes the Fault Lines Beneath Moderna’s 540% Run

angelina -

Moderna’s 133% Monthly Surge Meets Wall Street’s Cold Water

12Page 1 of 2